Vildagliptin

Risk of hepatotoxicity

New Zealand. Medsafe has announced that hepatotoxicity is the most significant risk of harm with vildagliptin.

Vildagliptin is a potent and selective dipeptidyl-peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes.

Medsafe encourages healthcare professionals to perform liver function tests before starting and stopping treatment. Also, the use of vildagliptin should be avoided during pregnancy unless the expected benefits outweigh any potential risks.

The CARM received 15 reports where vildagliptin was suspected. The 15 reports describe 36 reactions, including hepatic reactions, oedema, cardiac disorders, mood disorders and gastrointestinal disorders.

Reference : Prescriber Update, Medsafe, September 2019